TGF-β-Induced profibrotic signaling is regulated in part by the WNT receptor Frizzled-8

Spanjer, Anita I. R.; Baarsma, Hoeke A.; Oostenbrink, Lisette M.; Jansen, Sepp R.; Kuipers, Christine C.; Lindner, Michael; Postma, Dirkje S.; Meurs, Herman; Heijink, Irene H.; Gosens, Reinoud

Published in:
The FASEB Journal

DOI:
10.1096/fj.201500129

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2016

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license. More information can be found on the University of Groningen website: https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment.

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
TGF-β-induced profibrotic signaling is regulated in part by the WNT receptor Frizzled-8

Anita I. R. Spanjer,†,† Hoeka A. Baarsma,‡ Lisette M. Oostenbrink,‡ Sepp R. Jansen,†,† Christine C. Kuipers,*,† Michael Lindner,§ Dirkje S. Postma,†,§ Herman Meurs,*,† Irene H. Heijink,*,†,§ Reinoud Gosens,*,†,1,2 and Melanie Königshoff,‡,1,3

†Department of Molecular Pharmacology, University of Groningen, Groningen, The Netherlands; ‡Comprehensive Pneumology Center, Helmholtz Center Munich, German Center for Lung Research (DZL), University Hospital Grosshadern, Ludwig Maximilians University Munich, Munich, Germany; §Asklepios Fachkliniken München-Gauting, Munich, Germany; and †Department of Pulmonology, 1Department of Pathology and Medical Biology, Experimental Pulmonology and Inflammation Research, and 2Groningen Research Institute for Asthma and COPD (GRIAC), University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

ABSTRACT TGF-β is important in lung injury and remodeling processes. TGF-β and Wingless/integrase-1 (WNT) signaling are interconnected; however, the WNT ligand-receptor complexes involved are unknown. Thus, we aimed to identify Frizzled (FZD) receptors that mediate TGF-β-induced profibrotic signaling. MRC-5 and primary human lung fibroblasts were stimulated with TGF-β1, WNT-5A, or WNT-5B in the presence and absence of specific pathway inhibitors. Specific small interfering RNA was used to knock down FZD8. In vivo studies using bleomycin-induced lung fibrosis were performed in wild-type and FZD8-deficient mice. TGF-β1-induced FZD8 specifically via Smad3-dependent signaling in MRC-5 and primary human lung fibroblasts. It is noteworthy that FZD8 knockdown reduced TGF-β1-induced collagen Iα1, fibronectin, versican, α-smooth muscle (sm)-actin, and connective tissue growth factor. Moreover, bleomycin-induced lung fibrosis was attenuated in FZD8-deficient mice in vivo. Although inhibition of canonical WNT signaling did not affect TGF-β1-induced gene expression in vitro, noncanonical WNT-5B mimicked TGF-β1-induced fibroblast activation. FZD8 knockdown reduced both WNT-5B-induced gene expression of fibronectin and α-sm-actin, as well as WNT-5B-induced changes in cellular impedance. Collectively, our findings demonstrate a role for FZD8 in TGF-β-induced profibrotic signaling and imply that WNT-5B may be the ligand for FZD8 in these responses.—Spanjer, A. I. R., Baarsma, H. A., Oostenbrink, L. M., Jansen, S. R., Kuipers, C. C., Lindner, M., Postma, D. S., Meurs, H., Heijink, I. H., Gosens, R., Königshoff, M. TGF-β-induced profibrotic signaling is regulated in part by the WNT receptor Frizzled-8. FASEBJ. 30, 1823–1835 (2016). www.fasebj.org

Key Words: airway remodeling · extracellular matrix · myofibroblast differentiation · WNT signaling

Fibroblasts in the parenchyma and airways are the primary cells contributing to extracellular matrix (ECM) deposition and turnover in the lung. In this way, fibroblasts are important mediators influencing physiologic repair processes and tissue homeostasis. However, in pathologic conditions, as in the case of airway and pulmonary fibrosis, fibroblast function is altered, leading to myofibroblast differentiation and abnormal changes in ECM expression and composition (1, 2).

A key player in fibroblast activation is TGF-β. TGF-β is a profibrotic growth factor that activates fibroblasts, thereby stimulating ECM production and initiating myofibroblast differentiation (1, 3, 4). Myofibroblasts are characterized by a more contractile profile than fibroblasts and show an increased expression of markers such as α-smooth muscle (sm)-actin, connective tissue growth factor (CTGF), type III collagen, and plasminogen activator inhibitor (PAI) 1 (5–7).

Recent findings indicate similar key roles for the Wingless/integrase-1 (WNT) signaling pathway in tissue homeostasis and remodeling in many organ systems, including the lung (8–12). WNT ligands bind to transmembrane Frizzled (FZD) receptors and can thereby control cell differentiation, growth, and polarity in a variety of cell systems. FZD receptors activate either the canonical pathway, which signals to β-catenin, or one of the noncanonical pathways, which signal mainly to calcium (WNT/Ca²⁺ pathway) or to RhoA/JNK (WNT/planar cell polarity pathway) (13–16).

Abbreviations: CI, cell index; COPD, chronic obstructive pulmonary disease; CTGF, connective tissue growth factor; Cytotest, cytotox test; CTG, connective tissue growth factor; CytoTBS, cyto-TBS containing 0.1% Tween 20; DKK, Dickkopf; ECM, extracellular matrix; FBS, fetal bovine serum; FZD, Frizzled; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; HRP, horseradish peroxidase; LRP, lipoprotein receptor-related (continued on next page)
We previously demonstrated that TGF-β signaling increased the expression of WNT ligands and FZD receptors in human lung fibroblasts, of which the induction of FZD8 was most profound. We furthermore showed that TGF-β-induced fibronectin and α-sm-actin expression was dependent on β-catenin (10, 11). This underscores the role of WNT signaling in fibroblast activation and remodeling as well as the cross-talk that exists between TGF-β and WNT signaling in these responses. However, the exact functional roles of individual WNT ligands and FZD receptors such as FZD8 in these processes are still largely unknown. In the present study, we therefore investigated the functional role of FZD8 in TGF-β signaling both in vitro and in vivo. We show that FZD8 is involved in TGF-β signaling in bleomycin-induced fibrosis using wild-type and FZD8-deficient mice. In addition, we demonstrate that FZD8 plays a role in TGF-β-induced ECM turnover and myofibroblast differentiation, and we provide evidence that WNT-5B is its ligand in these responses.

MATERIALS AND METHODS

Ethics statement

Primary human lung fibroblasts were obtained from resected human lung tissue from the Asklepios biobank for lung diseases at the Comprehensive Pneumology Center and isolated as previously described (17). All participants gave written informed consent, and the study was approved by the Ludwig-Maximilians University Ethics Committee. The animal experiments were done in accordance with the guidelines of the ethics committee of the Helmholtz Zentrum München, as approved by the Regierungspräsidium Oberbayern, Germany.

Cell culture

MRC-5 human lung fibroblasts (18) were cultured in Ham’s F12 medium supplemented with 10% (v/v) fetal bovine serum (FBS), 2 mM l-glutamine, 50 μg/ml streptomycin, 50 U/ml penicillin, and 1.5 μg/ml amphotericin B at 37°C with 5% CO2. Before stimulation, cells were grown to confluence in 6-well cluster plates and serum deprived in supplemented medium with 0.5% (v/v) FBS for 24 h. Primary human lung fibroblasts were cultured in DMEM/Ham’s F12 (1:1) with 20% (v/v) fetal calf serum and 100 μg/ml streptomycin and 100 U/ml penicillin at 37°C with 5% CO2. Before stimulation, cells were grown to confluence and serum deprived for 24 h in medium with 0.1% fetal calf serum and 100 μg/ml streptomycin and 100 U/ml penicillin.

Cell stimulation

Pulmonary fibroblasts were stimulated with either 2 ng/ml recombinant TGF-β1, 1 μg/ml recombinant WNT-5A, or 1 μg/ml recombinant WNT-5B. The inhibitors Dickkopf (DKK)-1 (0.3 μg/ml), SIS3 (3 μM), U-0126 (3 μM), Y-27632 (1 μM), PKF 115-584 (0.1 μM), and LY-294002 (3 μM) were added 30 min before stimulation. The concentrations of these inhibitors were chosen on the basis of their selectivity profiles as described in literature (19-23) and their effectiveness against their respective targets in our cell system (unpublished results).

Small interfering RNA transfection

Cells were grown to 90% confluence and transfected with specific small interfering (si)RNA against the FZD8 transcript. Cells were transfected in serum-free Ham’s F12 without supplements using 100 pmol FZD8-targeted siRNA or nontargeting control siRNA and Lipofectamine 2000 Transfection Reagent (Invitrogen, Paisley, United Kingdom). After 6 h the medium was changed to supplemented medium with 10% (v/v) FBS for 18 h and subsequently to supplemented medium with 0.5% (v/v) FBS for 24 h. Cells were stimulated as described above.

mRNA isolation and real-time PCR analysis

Total mRNA of MRC-5 human lung fibroblasts was extracted using the NucleoSpin RNA II kit (Macherey-Nagel, Düren, Germany). Total mRNA of primary human lung fibroblasts and of the mouse lungs was extracted using peqGold Total RNA Kit including the DNase digestion (Peqlab, Erlangen, Germany). The eluted mRNA was quantified using spectrophotometry (Nanodrop; Thermo Scientific, Wilmington, DE, USA). Equal amounts of mRNA (1 μg) were then reverse transcribed according to the Reverse Transcription System (Promega Benelux, Leiden, The Netherlands), and the cDNA was stored at −20°C until further use. A total of 5 μl Absolute Blue SYBR Green Supermix, containing fluorescent to comprise well-to-well variation, a 1 μM concentration of gene-specific forward and reverse primer, and 1 μl of cDNA sample were used in a total volume of 10 μl in a 48-well plate. The sequences of the primers used for determining genes of interest are listed in Tables 1 and 2. Gene expression was determined using real-time PCR, which was performed with the Illumina Eco Personal QPCR System (Westburg, Leusden, The Netherlands). Real-time PCR data were analyzed using the comparative cycle threshold method.

Smad binding element-4 activity

MRC-5 human lung fibroblasts were plated on 6-well plates and transfected as described above with 0.5 μg plasmid DNA encoding Smad binding element (SBE)-4-firefly luciferase and 0.12 μg plasmid DNA encoding CMV-Renilla luciferase. SBE-4 activity is a measure of activation of TGF-β/SMAD signaling. Transfected cells were then stimulated with TGF-β1 (2 ng/ml) in the presence or absence of SIS3 (3 μM) as described above. After 24 h, cells were lysed. Subsequently, firefly luciferase and Renilla luciferase activity were measured using a Luminometer (Luminoskan Ascent, Thermo Electron, Waltham, MA, USA) and using the Dual-Luciferase Reporter Assay (Promega Benelux). Firefly luciferase activity was normalized against Renilla luciferase activity.

Western blot analysis

To obtain whole-cell lysates, cells were washed once with ice-cold (4°C) HBSS [composition (mg/L): 400 KCl, 60 KH2PO4, 8000 NaCl, 350 NaHCO3, 50 Na4HPO4, 1H2O, 1000 glucose; pH 7.4], then lysed in ice-cold sodium doxycyl sulfate buffer (composition: 625 mM Tris, 2% w/v sodium doxycyl sulfate, 1 mM NaF, 1 mM

(continued from previous page)
**FZD8 REGULATES PROFIBROTIC SIGNALING**

**TABLE 1. Primers used for determination of specific human genes of interest**

<table>
<thead>
<tr>
<th>Gene</th>
<th>Forward</th>
<th>Reverse</th>
</tr>
</thead>
<tbody>
<tr>
<td>FZD1</td>
<td>TCG ACT TCC TAG AGC TGG AT</td>
<td>AAG GTG GGA GAA GGG AGT TA</td>
</tr>
<tr>
<td>FZD2</td>
<td>CCC GAC TGG CAT GGT CAT CAT</td>
<td>CTT TGG GAG CCA GTA TA</td>
</tr>
<tr>
<td>FZD3</td>
<td>TCT CTT TGG CCC TGG ACT G</td>
<td>ACA AAG AAA AGG CCG GAA AT</td>
</tr>
<tr>
<td>FZD4</td>
<td>CCA GAA TGT CTT CGG ACT G</td>
<td>CCA TGG CTT GCT GTA CTA GT</td>
</tr>
<tr>
<td>FZD5</td>
<td>AGC TAA AAT GGC CAG AGC AA</td>
<td>AAT TCC CCC TGG GAA CTA TG</td>
</tr>
<tr>
<td>FZD6</td>
<td>TGT TGT GGA TGG CTC GTC TG</td>
<td>CCA TGG ATT TGG AAA TGA CC</td>
</tr>
<tr>
<td>FZD7</td>
<td>CCA CGC TCT TTA CGG TCC TC</td>
<td>GCC ATG CGG AAG TAG AG</td>
</tr>
<tr>
<td>FZD8</td>
<td>GAC ACT TGA TGG CTT GAG GT</td>
<td>CAA ATG TCG GTG TCT GGA AA</td>
</tr>
<tr>
<td>FZD9</td>
<td>AGA CCA TCG TCA TCG TGA CC</td>
<td>CCA TGA GCT TGT CGT GCA TT</td>
</tr>
<tr>
<td>FZD10</td>
<td>CTT CCA AGA CTC TGC AGT CC</td>
<td>GAC TGG GCA GAG ATC TCA TA</td>
</tr>
<tr>
<td>Collagen Ix1</td>
<td>AGC CAG GAG AGT GAG AAT TG</td>
<td>TCT TGT CTT TGG GTG TCT TG</td>
</tr>
<tr>
<td>Type III collagen</td>
<td>TCG CAG AGG AAA TTT CAA TG</td>
<td>AGA CAC GTG GAC CTC ATC AT</td>
</tr>
<tr>
<td>Fibronectin</td>
<td>TCG AGG AGG AAA TTT CAA TG</td>
<td>ACA CAC GTG GAC CTC ATC AT</td>
</tr>
<tr>
<td>Versican</td>
<td>CCA TGA ATG GTG GGT TTG AG</td>
<td>GTG TTT AGT GCA ACC ATC</td>
</tr>
<tr>
<td>α-sm-Actin</td>
<td>GAC CCT GAA GTA CCC GAT AGA AC</td>
<td>GGG CAA CAG GAA GAT CAT TG</td>
</tr>
<tr>
<td>CTGF</td>
<td>GGA AAA GAT TGC GAC CCA AT</td>
<td>TGG TCC TAA AGC CAG ACC TT</td>
</tr>
<tr>
<td>PAI-1</td>
<td>CCG CAG AGG ACG AGG AA</td>
<td>GGA CAC ATG TGC ATC GTG AAC T</td>
</tr>
<tr>
<td>Wnt-5A</td>
<td>GGC TGG GAA CCA AAA AGG AT</td>
<td>TGG AAT CTA CCC ATC CTA TA</td>
</tr>
<tr>
<td>Wnt-5B</td>
<td>AGC TGT GAC ATG TCT GAG GA</td>
<td>CGA GGT TGA AGC GTC CC</td>
</tr>
<tr>
<td>Axin2</td>
<td>CCT GCC ACC AAG ACC TAC AT</td>
<td>CTT CAT TCA AGG TGG GAA GA</td>
</tr>
<tr>
<td>HPRT</td>
<td>AAG GCC CCC AGG AAG TGT TG</td>
<td>GGC TTT GTA TTT GTC TTT TCC A</td>
</tr>
<tr>
<td>18S rRNA</td>
<td>CGC CGG TAG AGG TGA AAT TC</td>
<td>TTG GCA AAT GTC TTT CTC G</td>
</tr>
</tbody>
</table>

**TABLE 2. Primers used for determination of specific mouse genes of interest**

<table>
<thead>
<tr>
<th>Gene</th>
<th>Forward</th>
<th>Reverse</th>
</tr>
</thead>
<tbody>
<tr>
<td>FZD8</td>
<td>GCA AGG AGG CCC AAC TAA GAC</td>
<td>GAG GCC CAA GGG GAT CA</td>
</tr>
<tr>
<td>Axin2</td>
<td>AGC AGA GGG ACA GGA ACC A</td>
<td>CAG TGG CCA GTG TCT TGG GCT</td>
</tr>
<tr>
<td>Fibronectin</td>
<td>GGT GTA GCA CAA CCT GCA ATT ACG</td>
<td>GGA ATT TCC CGG TGG AGT CT</td>
</tr>
<tr>
<td>HPRT</td>
<td>CCT AAG ATG AGG GCA AGT TGA A</td>
<td>CCA CAG GAC TAG AAG ACC TGG TAA</td>
</tr>
</tbody>
</table>

Na<sub>2</sub>VO<sub>4</sub>, 10 mg/mL aprotinin, 10 mg/mL leupeptin, 7 mg/mL peptatin A, pH 6.8). Protein concentration was determined in whole-cell lysates and whole lung homogenates using a Pierce BCA protein determination assay (Thermo Fisher Scientific, Rockford, IL, USA). Lysates were stored at −20°C until further use. Equicalit quantities of protein (10–20 μg per lane) were subjected to electrophoresis on polyacrylamide gels and transferred to nitrocellulose membranes. These were analyzed for proteins of interest using specific primary antibodies and horseradish peroxidase (HRP)-conjugated secondary antibodies. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), ß-actin, or ß-tubulin was used as a loading control. By using chemiluminescence reagents, bands were recorded in the G:BOX iChemtl gel documentation system equipped with GeneSnap image acquisition software (Syngene, Cambridge, United Kingdom). Band intensities were quantified by densitometry using GeneTools analysis software (Syngene).

**Immunocytochemistry**

MRC-5 human lung fibroblasts were grown to confluence on Lab-Tek borosilicate chamber slides and changed to supplemented medium with 0.5% (v/v) FBS for 24 h before stimulation. Cells were stimulated with 2 ng/mL recombinant TGF-β1, 1 μg/mL recombinant WNT-5A, or 1 μg/mL recombinant WNT-5B for 48 h, then fixed for 15 min at room temperature in cytoskeletal buffer (composition: 10 mM MES, 150 mM NaCl, 5 mM EGTA, 5 mM MgCl<sub>2</sub>, 5 mM glucose, pH 6.1) containing 3% paraformaldehyde. Cells were then permeabilized by incubation for 5 min at room temperature in cytoskeletal buffer containing 3% paraformaldehyde and 0.3% Triton X-100. Fixed cells were then blocked for 2 h at room temperature in Cyto-Tris-buffered saline (TBS) buffer (20 mM Tris base, 154 mM NaCl, 2.0 mM EGTA, 0.2 mM MgCl<sub>2</sub>, pH 7.2) containing 1% bovine serum albumin and 2% normal donkey serum. Incubation with primary antibody (mouse anti-α-sm-actin, diluted 1:100) happened overnight at 4°C in Cyto-TBS containing 0.1% Tween 20 (Cyto-TBST). Incubation with Cy3-conjugated secondary antibody was done for 2 h at room temperature in Cyto-TBST. Nuclei were stained with Hoechst dye 33342. After staining, coverslips were mounted using ProLong Gold antifade reagent (Invitrogen) and analyzed using an Olympus AX70 microscope equipped with digital image capture system (ColorView Soft System with Olympus U CMAD2 lens; Olympus, Tokyo, Japan).

**Impedance measurement**

WNT-5B-mediated cellular activation was assessed using the xCELLigence system (Roche Applied Science, Penzberg, Germany) using E-plates (ACEA Biosciences, San Diego, CA, USA).
Impedance was measured by integrated microelectronic sensor arrays in the bottom of the E-plates. Electrode impedance can be affected by changes in intracellular mass redistribution and provides a means to assess activation of ligand-receptor complexes in living cells in real time (24). Changes in impedance were measured and converted to the relative and dimensionless cell index (CI) using the Real-Time Cell Analyzer software (Roche Applied Science; ACEA Biosciences). CI represents the impedance change divided by a background value: CI = (Zi − Zo)/15 Ω. The change in impedance is represented by the impedance at an individual time point (Zi) during the experiment minus the background and electrical resistance measured in the absence of cells before the experiment (Zo). MRC-5 human lung fibroblasts were transfected as described above with specific FZD8-targeted siRNA or nontargeting control siRNA. At 24 h after transfection, cells were trypsinized and plated in 16-well E-plates in supplemented or nontargeting control siRNA. At 24 h after transfection, cells were measured and converted to the relative and dimensionless cell index (CI) using the CI value change divided by a background value: CI = (zi − zo)/15 Ω. If cells respond to stimulation, CI will change immediately. Therefore, before stimulation with ligands, CI was measured at 1 s intervals. Cells were stimulated with recombinant WNT-3A (2-aminophenylthio)butadiene (U-0126), (+)-(R)-trans-4-(1 aminoethyl)-N-(4-pyridyl) cyclohexane carboxamide (Y-27632), and 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY-294002) were obtained from Tocris Cookson (Bristol, United Kingdom). PKF 115-584 was obtained from Novartis Pharma AG (Basel, Switzerland). FZD8 siRNA was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and nonsilencing control siRNA from Qiagen (Germantown, MD, USA). Lipoectamine 2000 Transfection Reagent and Hoechst 33342 were obtained from Invitrogen (Carlsbad, CA, USA). Mouse anti-α-sm-actin, mouse anti-β-actin, HRP-conjugated goat antimouse antibody, and HRP-conjugated rabbit anti-goat antibody were purchased from Sigma-Aldrich (St. Louis, MO, USA). Rabbit anti-fibronectin (H-300) antibody, goat anti-fibronectin (C20) antibody, and mouse anti-GAPDH antibody were obtained from Santa Cruz Biotechnology. Rabbit anti-phospholipoprotein receptor-related protein (LRP) (Ser1490) antibody and rabbit anti-β-tubulin were obtained from Cell Signaling (Bioké, Leiden, The Netherlands). All other chemicals were of analytical grade.

Preparation of WNT-3A-conditioned medium

Mouse L cells [subcutaneous fibroblasts; American Type Culture Collection (ATCC), Wesel, Germany] stably expressing WNT-3A were used to obtain WNT-3A-conditioned medium. Conditioned medium obtained from parental L cells was used as a control. Conditioned medium was prepared as per ATCC guidelines.

Animal studies

Heterozygous, inbred, specific-pathogen-free breeding colonies of FZD8−/− mice (C57BL/6;129P2-FZD8−/−gen) (13), showing no obvious phenotype, were obtained from The Jackson Laboratory (Bar Harbor, ME, USA). After breeding, homozygous FZD8−/− mice and wild-type (WT) littermates were used for experiments. Mice (8–12 wk) were sedated intraperitoneally with a combination of 0.2 mg/ml medetomidine (Orion Pharma, Hamburg, Germany), 2.0 mg/ml midazolam (Roche Pharma, Mannheim, Germany), and 0.02 mg/ml phenylant (Janssen-Cilag, Neuss, Germany), according to the animal’s body weight. A total of 30 μl becloxycin (Sigma-Aldrich, Taufkirchen, Germany) in PBS (3 U/kg) or PBS was intratracheally instilled through a MicroSprayer Aerosolizer 20 G INTROCAN (Penn Century, Wyndmoor, PA, USA). After installation, the narcosis was antagonized by a combination of 0.29 mg/ml atipamezole (Orion Pharma), 0.059 mg/ml flumazenil (Hexal, Holzkirchen, Germany), and 0.14 mg/ml naloxone (Actavis, Munich, Germany) according to body weight. On d 14 after becloxycin installation, the mice were sedated according to body weight with 0.14% (v/v) ketamine (Pharma Partner, Hamburg, Germany) and 0.03% (v/v) xylazine (Prozykta, Bela Pharma, Vechta, Germany) in 0.9% sodium chloride. Lung lobes were snap frozen and stored at −80°C before mRNA isolation and protein determination, and 1 lobe was filled with 4% paraformaldehyde for histology. Paraffin-embedded sections were stained with hematoxylin and eosin and Masson-Goldner (Carl Roth, Karlsruhe, Germany) to evaluate collagen deposition. Staining intensity was quantified by ImageJ (25).

Antibodies and reagents

Recombinant human TGF-β1, recombinant human DKK-1, recombinant human/mouse WNT-5A, and recombinant mouse WNT-5B were obtained from R&D Systems (Minneapolis, MN, USA). 6,7-Dimethyl-2-{[(2E)-3-(1-methyl-2-phenyl-1H-pyrrolo [2,3-b]pyridin-3-yl)prop-2-en-1-yl]-1,2,5,4-tetrahydroisquinoline hydrochloride (SIS3) was obtained from Merck GmbH (Darmstadt, Germany). 1,4-Diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene (U-0126), (+)-(R)-trans-4-(1-aminoethyl)-N-(4-pyridyl) cyclohexane carboxamide (Y-27632), and 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY-294002) were obtained from Tocris Cookson (Bristol, United Kingdom). PKF 115-584 was obtained from Novartis Pharma AG (Basel, Switzerland). FZD8 siRNA was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and nonsilencing control siRNA from Qiagen (Germantown, MD, USA). Lipoectamine 2000 Transfection Reagent and Hoechst 33342 were obtained from Invitrogen (Carlsbad, CA, USA). Mouse anti-α-sm-actin, mouse anti-β-actin, HRP-conjugated goat antimouse antibody, and HRP-conjugated rabbit anti-goat antibody were purchased from Sigma-Aldrich (St. Louis, MO, USA). Rabbit anti-fibronectin (H-300) antibody, goat anti-fibronectin (C20) antibody, and mouse anti-GAPDH antibody were obtained from Santa Cruz Biotechnology. Rabbit anti-phospholipoprotein receptor-related protein (LRP) (Ser1490) antibody and rabbit anti-β-tubulin were obtained from Cell Signaling (Bioké, Leiden, The Netherlands). All other chemicals were of analytical grade.

Statistical analysis

All real-time PCR data were log transformed before statistical analysis. For comparison between 2 conditions, a Student’s t test or Mann-Whitney U test was used, as appropriate. For comparisons between multiple conditions, 1-way repeated-measures ANOVA was used, followed by a post hoc analysis using the Student-Newman-Keuls multiple-comparisons test. For comparisons of the in vivo experiments, 2-way ANOVA was used, followed by a post hoc analysis using the Student-Newman-Keuls multiple-comparisons test. P < 0.05 was considered significant.

RESULTS

TGF-β1-induced FZD8 gene and protein expression in human lung fibroblasts

We previously showed that TGF-β1 stimulation induced FZD8 expression in primary human lung fibroblasts (11). Here we extended these findings and investigated the regulation of FZD8 by TGF-β1 in more detail. We observed that TGF-β1 strongly and specifically induces FZD8 gene and protein expression in MRC-5 and primary human lung fibroblasts with little to no effect on other FZD receptor subtypes (Fig. 1A–F). The effect on FZD8 expression was already visible after 4 h of stimulation and was more pronounced after 24 h (Fig. 1B). The induction of FZD8 expression was concentration dependent, with an EC50 of 0.26 ng/ml for TGF-β1 and a maximal response at 2 ng/ml (18.5 ± 3.2-fold increase compared with untreated control; P < 0.001; Fig. 1C). TGF-β1 also increased FZD8 expression in primary human lung fibroblasts (Fig. 1E, F). Parallel with the induction of FZD8, TGF-β1 increased the expression of the ECM components collagen Iα1, fibronectin, and versican as well as...
Figure 1. TGF-β₁-induced FZD8 mRNA and protein expression in human lung fibroblasts is Smad3 dependent. MRC-5 human lung fibroblasts and primary human lung fibroblasts were stimulated with TGF-β₁ for 4 or 24 h (mRNA) or 48 h (protein). Specific inhibitors were used to block individual TGF-β₁ signaling pathways. A) Gene expression of FZD receptors in MRC-5 human lung fibroblasts after 24 h of stimulation with TGF-β₁ (2 ng/ml). Of note, high cycle threshold (Ct) values correspond to low copy numbers. Data represent the means ± SEM of 3–6 independent experiments. B) FZD8 expression in MRC-5 human lung fibroblasts after stimulation with TGF-β₁ (2 ng/ml) at different time points. Data represent the means ± SEM of 5 independent experiments. C) Concentration-dependent increase of FZD8 expression in MRC-5 human lung fibroblasts after 24 h of (continued on next page)
the differentiation markers α-sm-actin, PAI-1, and CTGF (Supplemental Fig. S1A). TGF-β1 dose-dependently increased the expression of fibronectin, versican, and CTGF, which are WNT-responsive genes (11, 26–29), with an EC50 of 0.14, 0.30, and 2.52 ng/ml, respectively (Supplemental Fig. S1B). On the basis of these data, we used a concentration of 2 ng/ml TGF-β1 and the 24 h time point for gene expression analysis in subsequent experiments.

TGF-β1-induced FZD8 expression in human lung fibroblasts is Smad3 dependent

TGF-β signals via several intracellular pathways involving Smad, MAPK/ERK, Rho kinase, β-catenin/T-cell factor (TCF), and phosphoinositide 3-kinase (PI3K) (30). To investigate via which pathway the induction of FZD8 by TGF-β1 is established, we used specific inhibitors of Smad3 (SIS3, 3 μM), MEK1/2, MEK1/2, Rho kinase (Y-27632, 1 μM), β-catenin/TCF, and PI3K (LY-294002, 3 μM). The concentrations of these inhibitors were chosen to provide (sub)maximal and selective inhibition of their respective targets in airway mesenchymal cells (19–23) (unpublished results). It is noteworthy that the TGF-β1-induced expression of FZD8 was attenuated by the Smad3 inhibitor (57%) but was not affected by the inhibition of MEK1/2, Rho-kinase, β-catenin/TCF, or PI3K signaling (Fig. 1G). These results demonstrate that TGF-β1-induced FZD8 expression in MRC-5 human lung fibroblasts is Smad3 dependent. Smad3 inhibition also blocked TGF-β1-induced SBE-4 activity, which was studied as a measure of activation of TGF-β/SMAD signaling (Supplemental Fig. S1C) and which impaired TGF-β1-induced expression of fibronectin, versican, and CTGF (Supplemental Fig. S1D–F).

TGF-β1-induced ECM expression and myofibroblast differentiation is regulated by FZD8

TGF-β activates fibroblasts, resulting in an enhanced ECM turnover and myofibroblast differentiation (2, 6, 7, 31, 32). We show that parallel with the induction of FZD8, TGF-β1 increased the gene expression of the ECM components collagen Iα1, fibronectin, and versican as well as the differentiation markers α-sm-actin, PAI-1, and CTGF (Supplemental Fig. S1A). To study a possible role for FZD8 in this process, we used specific FZD8-targeting siRNA. As a control, FZD8 knockdown reduced the gene expression of this receptor by 56% at baseline and almost completely prevented the induction of FZD8 expression in response to TGF-β1 (from 4.5 ± 1.5 to 0.6 ± 0.2-fold of baseline FZD8 expression in control siRNA-transfected cells; Fig. 2). FZD8 knockdown significantly reduced the TGF-β1-induced expression of collagen Iα1, fibronectin, versican, α-sm-actin, and CTGF but not PAI-1 (Fig. 2) and type III collagen (data not shown). The expression of these genes was differentially attenuated, with versican expression being the most affected (85% reduction), followed by CTGF (70%), fibronectin (60%), α-sm-actin (53%), and collagen Iα1 (38%). These results show that FZD8 is partly involved in the TGF-β1-induced gene expression of several ECM proteins and myofibroblast differentiation markers.

Bleomycin-induced fibrosis in mice is partially dependent on FZD8

Next, we investigated whether FZD8 also contributes to the development of lung fibrosis in vivo. To this end, FZD8+/− mice and WT littermates were instilled with bleomycin to induce fibrosis, a process highly dependent on TGF-β signaling (33). We first confirmed that FZD8 expression was reduced in FZD8+/− mice compared with WT mice (Fig. 3A). Single bleomycin instillation caused strong fibrotic alterations within the lung after 14 d, characterized by increased fibronectin and collagen deposition in the lungs of WT mice. Notably, collagen deposition was reduced by 34% (P < 0.05) and fibronectin protein expression by 57% (P < 0.05) in the lungs of bleomycin-subjected FZD8+/− mice compared with WT mice subjected to bleomycin (Fig. 3B–E).

TGF-β1-induced ECM expression and myofibroblast differentiation is not regulated via canonical WNT signaling

WNT signaling can occur via the canonical β-catenin-dependent pathway and via the noncanonical β-catenin-independent signaling pathways (13–15). Our previous studies showed that TGF-β1-induced α-sm-actin, collagen Iα1, fibronectin, and versican expression are regulated by β-catenin signaling (10, 11). We thus hypothesized that activation of FZD8 mediates canonical WNT signaling that might potentiate TGF-β1-induced ECM turnover and myofibroblast differentiation. We therefore studied the effects of endogenous canonical WNT signaling inhibition in the presence of TGF-β signaling. We applied the well-known WNT antagonist DKK-1, which targets the interaction of FZDs with the coreceptor low-density LRPs.6.
This coreceptor is indispensable for canonical WNT signaling (13). Interestingly, DKK-1 (0.3 μg/ml) had no effect at all on TGF-β1-induced gene expression, suggesting that FZD8 signals through noncanonical WNT signaling (Fig. 4A). As a positive control, DKK-1 inhibited the expression of the canonical WNT target gene Axin2, which was induced by WNT-3A-conditioned medium (Supplemental Fig. S2). In line with this, the expression of the canonical WNT target gene Axin2 was increased at basal levels in the FZD8−/− mice (Fig. 4B), and a similar trend was observed for activated β-catenin expression (data not shown), suggesting that FZD8 does not target the canonical pathway, as its presence functions as inhibitor. Further, TGF-β1 had no effect on ser1490 LRPS/6 phosphorylation in MRC-5 human lung fibroblasts, an event necessary for canonical WNT signaling (Fig. 4C).

Noncanonical WNT-5B is a ligand for FZD8

We previously demonstrated that TGF-β induces specific expression of the noncanonical ligand WNT-5B in human lung fibroblasts (11). In view of these and our current results, we investigated the expression of WNT-5B in MRC-5 human lung fibroblasts in response to TGF-β1. Indeed, TGF-β1 induced the expression of WNT-5B in a concentration-dependent manner, with an EC50 of 0.26 ng/ml (Fig. 5A). Similar to FZD8 expression, the TGF-β1-induced WNT-5B expression was Smad3 dependent (Fig. 5B). Functional studies showed that stimulation with recombinant WNT-5B mimicked the TGF-β1-induced gene expression of ECM components and differentiation markers; WNT-5B significantly induced the expression of fibronectin, versican, α-sm-actin, and CTGF (Fig. 5C). We confirmed these findings at the protein level for fibronectin and α-sm-actin (Fig. 5D, E). For these experiments, we used stimulation with recombinant WNT-5A as a control (Fig. 5C–E). This observation might imply that WNT-5B is a ligand for FZD8-mediated fibroblast activation. Thus, we studied the impact of FZD8 knockdown on WNT-5B-induced dynamic mass redistribution as a measure of ligand-mediated cellular activation. First, we showed that WNT-5B-induced changes in cellular impedance, a measure for ligand dependent receptor activation, are partially prevented by FZD8 knockdown (41%), confirming that WNT-5B engages FZD8 receptor signaling for fibroblast activation (Fig. 6A, B). Next, we studied the effect of FZD8 knockdown on WNT-5B-induced gene expression in MRC-5 human lung fibroblasts, focusing on the WNT-5B responsive genes fibronectin, versican, α-sm-actin, and CTGF. Indeed, the WNT-5B-induced expression of fibronectin (34%) and α-sm-actin (38%) was significantly downregulated by FZD8 knockdown, indicating that WNT-5B is dependent on FZD8 for the induction of these genes (Fig. 6C). Collectively, these data show that noncanonical WNT-5B is a ligand for FZD8 and that FZD8 regulates TGF-β1-induced ECM gene expression and myofibroblast differentiation in human lung fibroblasts.

**DISCUSSION**

We show for the first time that the FZD8 receptor in human lung fibroblasts is required in part for the effects of TGF-β on the expression of various ECM proteins and myofibroblast differentiation in vitro as well as for bleomycin-induced fibrosis in vivo. Furthermore, we demonstrate that these effects are established via noncanonical WNT signaling and that specifically WNT-5B functions as a ligand for FZD8 to mediate the effects of TGF-β on fibroblast activation. These findings provide supportive evidence that a signaling axis involving FZD8 and WNT-5B plays a role in TGF-β-induced ECM turnover and repair mechanisms.

Fibroblasts contribute to tissue repair and remodeling by regulating ECM turnover and by their differentiation into myofibroblasts (1, 6, 7). TGF-β activates fibroblasts, thereby stimulating ECM production and initiating myofibroblast differentiation, leading to a more contractile phenotype (3, 7, 31, 32, 34). Epithelial cells and inflammatory cells can secrete TGF-β, which can act on fibroblasts to induce ECM production and myofibroblast differentiation (35, 36). We observed here that TGF-β regulates the expression of ECM proteins and myofibroblast markers collagen Iα1, fibronectin, versican, α-sm-actin, and CTGF in a FZD8-dependent manner in human lung fibroblasts. The induction of PAI-1, however, was unaffected by FZD8 knockdown. In addition, not all genes were attenuated by FZD8 knockdown to the same extent. Whereas versican and CTGF were nearly completely inhibited, collagen Iα1, fibronectin, and α-sm-actin were only partially inhibited. In vivo, bleomycin exposure induced the expression of both collagen and fibronectin, which were partially inhibited in FZD8-deficient mice. This indicates that signaling via FZD8 is to some degree specific for individual ECM components and that other mechanisms (e.g., Smad3-dependent gene transcription) play
Figure 3. Bleomycin-induced fibrosis in mice is partially dependent on FZD8. FZD8−/− mice and WT littermates were instilled with bleomycin to induce fibrosis and followed up after 14 d as described in Materials and Methods. A) FZD8 expression in whole lung tissue. Data represent the means ± SEM of 5–8 mice per group. **P < 0.01 compared with control WT mice, ***P < 0.001 compared with control WT mice (2-way ANOVA with Student-Newman-Keuls multiple-comparisons test). B, C) Fibronectin gene expression (B) and fibronectin protein expression (C) in whole lung tissue. Data represent the means ± SEM of 3–6 mice per group. **P < 0.01 compared with control WT mice, ***P < 0.001 and ###P < 0.001 compared with bleomycin-instilled WT mice, $P < 0.05$ compared with PBS-treated FZD8−/− mice (2-way ANOVA with Student-Newman-Keuls multiple-comparisons test). D) Histologic assessment of fibrotic areas in lung using Masson-Goldner staining. Data represent the means ± SEM of 5–8 mice per group. ***P < 0.001, **P < 0.01 compared with control WT mice, $P < 0.05$ compared with bleomycin-instilled WT mice (2-way ANOVA with Student-Newman-Keuls multiple-comparisons test). E) Representation for quantification of staining shown in (D).
additional regulatory roles in the TGF-β-induced expression of these components. Of importance, TGF-β induced the expression of both FZD8 and WNT-5B in a Smad3-dependent manner. We also show that WNT-5B is induced in response to TGF-β with a similar EC₅₀ as that observed for FZD8 induction.

Our findings strongly suggest that WNT-5B can function as an endogenous ligand for the FZD8 receptor. This is supported by several observations. First, we confirmed our previous findings showing that WNT-5B is highly expressed in human lung fibroblasts (11). WNT-5B expression was also Smad3 dependent, and it mimicked the functional effects of TGF-β on the induction of fibronectin, versican, α-sm-actin, and CTGF expression as well as fibronectin and α-sm-actin expression. In addition, WNT-5B-induced changes in cellular impedance were partially prevented by FZD8 knockdown, indicating that WNT-5B engages FZD8 receptor signaling. Finally, our results showed that FZD8 is required for the induction of fibronectin and α-sm-actin expression by WNT-5B. Collectively, this implies that TGF-β activates a WNT-5B/FZD8 ligand-receptor complex that is required for the induction of fibronectin and α-sm-actin and that this complex plays a regulatory role in the induction of collagen Iα1, versican, and CTGF expression. We did not observe functional effects of WNT-5A on ECM production in our current study; however, WNT-5A is known to regulate fibroblast proliferation (37), and our previous findings indicate that in airway smooth muscle, TGF-β induces the expression of both WNT-5A and FZD8. In that study, we showed that both WNT-5A and FZD8 knockdown reduced ECM production in response to TGF-β (12). Thus, the role of WNT-5A may be cell specific or context specific, as the WNT ligand and receptor profile expressed by airway smooth muscle cells and fibroblasts do not completely overlap (11, 12).

The WNT signaling pathway operates through canonical β-catenin-dependent and noncanonical β-catenin-independent signaling routes (13–16). Although TGF-β is known to activate β-catenin (11), our current data show that the canonical WNT signaling pathway is not involved in TGF-β-induced ECM gene expression. We blocked the
Figure 5. Noncanonical WNT-5B mimics effects of TGF-β1 on fibroblast activation. MRC-5 human lung fibroblasts were stimulated with TGF-β1 (2 ng/ml), WNT-5A (1 μg/ml), or WNT-5B (1 μg/ml) for 24 h (mRNA) or for 48 h (protein and immunocytochemistry). A) Concentration-dependent increase of WNT-5B expression after stimulation with increasing concentrations of TGF-β1 (EC50, 0.26 ng/ml). Data represent means ± SEM of 5–8 independent experiments. B) Effect of inhibiting Smad3 on TGF-β1-induced gene expression of WNT-5B. Data represent the means ± SEM of 5 independent experiments. C) Recombinant TGF-β1-, WNT-5A-, and WNT-5B-induced effects on gene expression of ECM components and myofibroblast differentiation markers. Data represent the means ± SEM of 3–7 independent experiments. D) Effect of recombinant TGF-β1, WNT-5A, and WNT-5B on protein expression of fibronectin and α-sm-actin. Data represent the means ± SEM of 3–5 independent experiments. E) Effect of TGF-β1, WNT-5A, and WNT-5B stimulation on α-sm-actin stress fiber formation. Cells were stained for α-sm-actin (red) and DNA (Hoechst 33342; blue). Original magnification, ×100. ***P < 0.001, **P < 0.01, *P < 0.05 compared with basal conditions (Student’s t test; A, C, D). **P < 0.01, *P < 0.05 compared with basal conditions, ##P < 0.01 compared with stimulated control, $$P < 0.01 compared with inhibited control (1-way repeated-measures ANOVA with Student-Newman-Keuls multiple-comparisons test; B).
 canonical pathway using DKK-1, which interferes with the interaction between the FZD receptor and the LRP5/6 coreceptor necessary for canonical pathway activation (13). Inhibiting the canonical pathway had no effect at all on the TGF-\(\beta\)-induced effects, whereas it did inhibit WNT-3A-induced \(Axin2\) expression. Furthermore, stimulation with TGF-\(\beta\) did not result in LPR5/6 phosphorylation, an event necessary for canonical WNT signaling, whereas TGF-\(\beta\) did promote the expression of noncanonical WNT-5B. In turn, WNT-5B mimicked the TGF-\(\beta\) effects via the FZD8 receptor. In vivo, expression of the canonical WNT signaling target gene \(Axin2\) and activated \(\beta\)-catenin were not reduced in the FZD8-deficient mice, or even significantly increased. This indicates that the signaling downstream of TGF-\(\beta\)/FZD8 is not via canonical WNT signaling, which is in apparent contrast to previous findings from us and others showing that TGF-\(\beta\) activates \(\beta\)-catenin in vitro and in vivo (10, 11, 38–44) and to the findings that \(\beta\)-catenin is required for TGF-\(\beta\)-induced ECM gene expression (10). However, in addition to canonical WNT signaling, Smad2/3 is also known to activate \(\beta\)-catenin expression (39, 40), and \(\beta\)-catenin can physically interact with Smad2/3/4 proteins to regulate target gene expression (45, 46). Together with previous publications (11, 47), our current data indicate, therefore, that TGF-\(\beta\) can activate \(\beta\)-catenin directly via PKB/PKB/glycogen synthase kinase (GSK), 3-dependent effects on \(\beta\)-catenin protein stability and ERK1/2-dependent effects on \(\beta\)-catenin gene expression without the requirement for canonical WNT signaling. This notion is supported by findings showing that

Figure 6. WNT-5B functions as ligand for FZD8. WNT-5B mediated cellular activation was assessed as described in Materials and Methods. MRC-5 human lung fibroblasts were transfected as described with specific FZD8-targeted siRNA or nontargeting control siRNA. Cells were stimulated with recombinant WNT-5B (1 \(\mu\)g/ml). Change in CI was determined using CI value just before WNT-5B addition and after stabilization. A) Tracing shows representative example measurement of effect of FZD8 knockdown on WNT-5B-induced changes in impedance as measure of receptor-mediated fibroblast activation. CI values are normalized against time = 0 min. B) Effect of FZD8 knockdown on WNT-5B-induced changes in impedance as measure of receptor-mediated fibroblast activation. Data represent the means ± SEM of 5 independent experiments. C) MRC-5 human lung fibroblasts were stimulated with WNT-5B (1 \(\mu\)l/ml) for 24 h. Expression of FZD8 was silenced with specific FZD8-targeting siRNA using nontargeting siRNA as control. This figure shows the effect of FZD8 knockdown on WNT-5B-induced gene expression of ECM components and myofibroblast differentiation markers. Data represent the means ± SEM of 6 independent experiments. ***,\(P < 0.001, \#P < 0.05\) compared with basal conditions, ****\(P < 0.001, \#\#P < 0.05\) compared with stimulated control (1-way repeated-measures ANOVA with Student-Newman-Keuls multiple-comparisons test).
DKK-1 has no effect on TGF-β-induced ECM protein production or β-catenin expression in human airway smooth muscle cells (12) and that TGF-β does not promote the expression of classic canonical WNT target genes such as Axin2 in human lung fibroblasts (11). When all results are taken together, this implies that FZD8 partly regulates WNT-5B and TGF-β-induced effects on fibroblast activation via noncanonical WNT signaling and that this signaling branch operates parallel to TGF-β-induced, WNT-independent β-catenin signaling to promote gene expression. Recent studies indicate the involvement of WNT signaling in tissue remodeling in many organ systems including the lung (8, 11, 37). Chronic lung diseases, such as chronic obstructive pulmonary disease (COPD) or idiopathic pulmonary fibrosis, are progressive and devastating diseases, characterized by lung function compromised by underlying inflammatory and remodeling mechanisms. To date, only limited treatment options that target the underlying lung injury and remodeling are available. Remodeling in COPD occurs mainly in the small airways, while in idiopathic pulmonary fibrosis the parenchymal lung tissue is mostly affected. However, both diseases are characterized by TGF-β-induced fibroblast activation and remodeling (48, 49). Our current data show that TGF-β-induced fibroblast activation in vitro and bleomycin-induced fibrosis in vivo, a process dependent on TGF-β signaling, is regulated via FZD8. Furthermore, WNT-5B contributes to TGF-β-induced fibroblast activation as a ligand that signals via FZD8. In line with these findings, it was recently reported that high FZD8 expression in lung tissue of patients with idiopathic pulmonary fibrosis correlates with more rapid disease progression (44). In addition, our published findings showed that the TGF-β-induced expression of WNT-5B and FZD8 is higher in fibroblasts of patients with COPD compared with fibroblasts of non-COPD control subjects (11). Collectively, our data provide evidence that signaling via the WNT-5B/FZD8 ligand-receptor complex may play an important role in ECM turnover and repair mechanisms in lung diseases. This pathway may play a role in chronic lung diseases, providing a rationale to further explore the therapeutic potential of this pathway.

The authors thank E. Schmitt (Novartis Pharma AG) for the generous gift of the PKF 115-584. They also thank M. H. Menzen and A. van den Berg for technical assistance. This work was supported in part by the Netherlands Lung Foundation (NLF; Grant 3.2.10.042). H.A.B. is supported by a postdoctoral fellowship from the European Respiratory Society (NLF; Grant 3.2.10.042). They also thank M. H. Menzen, M. H., Haalayko, A. J., Meurs, H., Kerstjens, H. A. M., and Gosens, R. (2011) β-Catenin signaling is required for TGF-β1-induced extracellular matrix production by airway smooth muscle cells. Am. J. Physiol. Lung Cell Mol. Physiol. 301, L565–L595.


Received for publication June 23, 2015. Accepted for publication January 8, 2016.